Hamilton Thorne Ltd. reported audited financial results for the quarter ended March 31, 2024. Financial Highlights included: 1st quarter sales increased 16% to $19.4 million; sales for the quarter increased 15% on a constant currency basis, on the high-end of guidance. Adjusted EBITDA increased 24% to $3.5 million or 18% of sales, in line with guidance. Organic sales growth was 9%. Gross profit margin was 52.4% for the quarter, up 182 bps versus the prior year. Net loss was $936 thousand. Confirming guidance for the full 2024 with sales range between $78 and $82 million, representing 10- 15% organic growth.

Hamilton Thorne Ltd., a client of our Bristol Investor Relations firm, is a leading provider of precision instruments, consumables, software and services to the Assisted Reproductive Technologies, research, and cell biology markets.

Read the full press release here: Hamilton Thorne Reports Record Revenue and EBITDA for the Quarter Ended March 31, 2024, and Confirms Annual Guidance